Brief: Allakos Says Topline Phase 3 Data From The Enigma 2 Study And Phase 2/3 Data From The Kryptos Study In Patients With Eosinophilic Gastrointestinal Diseases

Allakos

22/12/2021 24:23

Dec 21 (Reuters) - Allakos Inc  ALLK.O :
    * ALLAKOS ANNOUNCES TOPLINE PHASE 3 DATA FROM THE ENIGMA 2
STUDY
AND PHASE 2/3 DATA FROM THE KRYPTOS STUDY IN PATIENTS WITH
EOSINOPHILIC GASTROINTESTINAL DISEASES
    * BOTH ENIGMA 2 AND KRYPTOS STUDIES MET THEIR HISTOLOGIC
CO-PRIMARY ENDPOINTS
    * BOTH STUDIES DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON
PATIENT
REPORTED SYMPTOMATIC CO-PRIMARY ENDPOINTS

Source text for Eikon:  ID:nGNX2VnzKy 
Further company coverage:  ALLK.O 

 ((reuters.briefs@thomsonreuters.com;))